Service de Bioénergétique, Biologie Structurale et Mécanismes, URA 2096 CNRS, iBiTec-S, Commissariat à l'Energie Atomique-Saclay, 91191 Gif-sur-Yvette Cedex, France.
J Biol Chem. 2011 Feb 4;286(5):3552-69. doi: 10.1074/jbc.M110.155200. Epub 2010 Nov 22.
ATP-sensitive K(+) (K(ATP)) channels are the target of a number of pharmacological agents, blockers like hypoglycemic sulfonylureas and openers like the hypotensive cromakalim and diazoxide. These agents act on the channel regulatory subunit, the sulfonylurea receptor (SUR), which is an ABC protein with homologies to P-glycoprotein (P-gp). P-gp is a multidrug transporter expressed in tumor cells and in some healthy tissues. Because these two ABC proteins both exhibit multispecific recognition properties, we have tested whether SUR ligands could be substrates of P-gp. Interaction with P-gp was assayed by monitoring ATPase activity of P-gp-enriched vesicles. The blockers glibenclamide, tolbutamide, and meglitinide increased ATPase activity, with a rank order of potencies that correlated with their capacity to block K(ATP) channels. P-gp ATPase activity was also increased by the openers SR47063 (a cromakalim analog), P1075 (a pinacidil analog), and diazoxide. Thus, these molecules bind to P-gp (although with lower affinities than for SUR) and are possibly transported by P-gp. Competition experiments among these molecules as well as with typical P-gp substrates revealed a structural similarity between drug binding domains in the two proteins. To rationalize the observed data, we addressed the molecular features of these proteins and compared structural models, computerized by homology from the recently solved structures of murine P-gp and bacterial ABC transporters MsbA and Sav1866. Considering the various residues experimentally assigned to be involved in drug binding, we uncovered several hot spots, which organized spatially in two main binding domains, selective for SR47063 and for glibenclamide, in matching regions of both P-gp and SUR.
三磷酸腺苷敏感性钾 (K(ATP)) 通道是许多药理学药物的作用靶点,如降糖磺酰脲类药物等抑制剂,以及降压的克罗卡林和二氮嗪等开放剂。这些药物作用于通道调节亚基,即磺酰脲受体 (SUR),它是一种与 P-糖蛋白 (P-gp) 具有同源性的 ABC 蛋白。P-gp 是一种在肿瘤细胞和一些健康组织中表达的多药转运蛋白。由于这两种 ABC 蛋白都表现出多特异性识别特性,我们测试了 SUR 配体是否可以成为 P-gp 的底物。通过监测 P-gp 丰富囊泡的 ATP 酶活性来检测与 P-gp 的相互作用。抑制剂格列本脲、甲苯磺丁脲和米格列奈增加了 ATP 酶活性,其效力顺序与它们阻断 K(ATP) 通道的能力相关。开放剂 SR47063(克罗卡林类似物)、P1075(吡那地尔类似物)和二氮嗪也增加了 P-gp ATP 酶的活性。因此,这些分子与 P-gp 结合(尽管亲和力低于 SUR),并且可能由 P-gp 转运。这些分子之间的竞争实验以及与典型的 P-gp 底物的竞争实验揭示了两种蛋白质的药物结合域之间存在结构相似性。为了合理地解释观察到的数据,我们研究了这些蛋白质的分子特征,并比较了结构模型,通过同源性从最近解决的鼠 P-gp 和细菌 ABC 转运蛋白 MsbA 和 Sav1866 的结构进行了计算机模拟。考虑到实验上分配到参与药物结合的各种残基,我们发现了几个热点,这些热点在 P-gp 和 SUR 的匹配区域中组织成两个主要的结合域,分别对 SR47063 和格列本脲具有选择性。